Liver Cancer

Patients with hepatocellular carcinoma and Child-Pugh-B liver function appear to have worse overall survival following treatment with regorafenib in the REFINE trial.

Treatment-emergent adverse effects following therapy with fostrox plus lenvatinib among those with hepatocellular carcinoma appear to be manageable in a phase 1a/2a study.

Use of the surgical Epione robot will save a significant amount of time when performing surgery for patients with liver tumors and potentially other cancers, says Govindarajan Narayanan, MD.

The safety profile of durvalumab plus TACE and bevacizumab in patients with hepatocellular carcinoma in the phase 3 EMERALD-1 study appears to consistent with previous findings.

Data from the phase 3 RATIONALE-301 trial appear to support tislelizumab as a potential frontline treatment option for patients with unresectable hepatocellular carcinoma.

Adding TPST-1120 to atezolizumab and bevacizumab appears to improve progression-free survival compared with atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma.

Most adverse effects appear to be grade 1 or 2 among patients with hepatocellular carcinoma and other solid tumors associated with the MYC oncogene receiving OTX-2002 in the phase 1/2 MYCHELANGELO I trial.

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.

Camrelizumab and rivoceranib appear to be an appropriate novel, first-line regimen for unresectable hepatocellular carcinoma.

The new drug application for rivoceranib plus camrelizumab in unresectable hepatocellular carcinoma is supported by findings from the phase 3 CARES 310 study.

The safety profile of durvalumab plus tremelimumab among those with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial was comparable with the known profiles of each individual agent.

Patients with unresectable hepatocellular carcinoma receiving single tremelimumab regular interval durvalumab have a feasible immune-related adverse effect profile.

The FDA gives orphan drug designation to ezurpimtrostat, an investigational autophagy inhibitor that may benefit patients with hepatocellular carcinoma.

According to findings from a phase 2 clinical study, futibatinib may achieve benefit in patients with intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements.

Adjuvant atezolizumab plus bevacizumab may effectively combat recurrence after surgery in patients with early-stage hepatocellular carcinoma.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better outcomes than patients treated in the preceding decade, according to a recent study.

Patients diagnosed with locally advanced, hepatocellular carcinoma experience benefit in overall survival, progression-free survival, and time to disease progression following treatment with sorafenib and stereotactic body radiation therapy.

Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.

Lenvatinib in combination with blank-microsphere transarterial chemembolization and sequential microwave ablation demonstrates encouraging preliminary activity in patients with hepatocellular carcinoma.

Envafolimab in combination with lenvatinib and transarterial chemoembolization demonstrated efficacy and safety among patients with unresectable hepatocellular carcinoma.

Findings from the phase 3 HIMALAYA trial indicate that durvalumab with or without tremelimumab remained efficacious regardless of the presence of anti-drug antibodies in unresectable hepatocellular carcinoma.

Durvalumab plus tremelimumab has been recommended for approval in the European Union for treatment of advanced liver and lung cancers.

A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.

Patients with hepatocellular carcinoma may benefit from treatment with OTX-2002, a first-in-class epigenomic controller designed to downregulate c-Myc that recently received orphan drug designation from the FDA

Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.

Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.

The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.

Results from the phase 1/2 TAS-120-101 trial lead to the accelerated approval of futibatinib in patients with locally advanced or metastatic cholangiocarcinoma and an FGFR2 gene fusion or rearrangement.

The FDA has granted orphan drug designation to second-line GNS561 following the completion of a phase 1/2a trial evaluating the novel PPT1 inhibitor in liver cancer and cholangiocarcinoma.

Results from the phase 3 RATIONALE-301 trial showed improved overall survival for patients who were given frontline tislelizumab for unresectable hepatocellular carcinoma.